LDX001

LDX001 is a fictional small-molecule compound used in educational contexts to illustrate core concepts in medicinal chemistry and drug development. It is not an approved therapeutic, nor is it an established investigational product in clinical trials.

In standard teaching nomenclature, the prefix LDX stands for lead-discovery, and the numeric suffix distinguishes successive examples. LDX001 is described as targeting a hypothetical enzyme X, with a core bicyclic scaffold linked to a functional group that modulates activity and selectivity.

The compound is described as a reversible competitive inhibitor with in vitro potency in the low micromolar range against enzyme X in illustrative assays. It is presented as having a moderate physicochemical profile, with a calculated logP around 3 to 4, molecular weight near 330–360 Da, and limited solubility in water, making it a typical teaching example for balancing properties during lead optimization.

In educational materials, LDX001 is used to demonstrate structure-activity relationships, metabolic stability considerations, and the importance of ADME screening in lead optimization. It is not associated with any real patient data or regulatory filings.

No regulatory status exists for LDX001 because it is a fictional construct created for instructional purposes.